OPIOMELANOCORTIN PEPTIDES AND CARDIOVASCULAR REGULATION

阿片黑皮质素肽和心血管调节

基本信息

  • 批准号:
    2901176
  • 负责人:
  • 金额:
    $ 19.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-01-14 至 2000-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from the application) The goal of this project is to test and further extend the hypothesis that the hypothalamic arcuate nucleus is a novel site of cardiovascular regulation, where stimulation of alpha-2 adrenergic receptors lowers blood pressure and heart rate by the release of the proopiomelanocortin (PMOC)-derived peptides beta-endorphin and alpha-MSH which, in turn, activate distinct opiate and melanocortin receptors located in the nucleus tractus solitarii (NTS). The proposed experiments will test several aspects of this hypothesis. Using genetically modified mice lacking the various alpha-2 AR sub types, as well as alpha-2 AR sub-type-specific antagonists in rats, we will define the alpha-2 AR sub-types in the arcuate nucleus which mediate hypotension and bradycardia. Inhibition of these effects in the NTS by anti-sera against the beta-endorphin and alpha-MSH or by antagonists of their respective receptors will be taken as evidence for the intermediary role of the two peptides. We will also test whether stimulation of arcuate alpha-2 AR can facilitate the baroreceptor reflex, and thus produce depressor effects indirectly. The relative role of such an indirect effect versus direct activation of the efferent baroreflex arc will be determined by comparing the hypotensive/ bradycardic response to intra-NTS injections of beta-endorphin or alpha-MSH in control and barodenervated animals. The link between hypothalamic alpha-2 AR and beta-endorphin/alpha-MSH will be further tested by measuring be biosynthetic rate of the two peptides in isolated hypothalami from rats chronically pre treated with vehicle or with alpha-methyldopa. These latter experiments will test whether the previously reported increase in hypothalamic POMC mRNA is reflected in increased peptide synthesis following alpha-methyldopa, and whether alpha-2 AR activation can differentially affect the processing of the two peptides. The results will help our understanding of anti hypertensive drug action, and will clarify the mechanism of cardiovascular regulation by POMC peptides.
描述:(改编自申请)这个项目的目标是

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
  • DOI:
    10.1016/s0014-2999(01)01112-8
  • 发表时间:
    2001-07
  • 期刊:
  • 影响因子:
    5
  • 作者:
    J. Wagner;Zoltán Járai;S. Batkai;George Kunos
  • 通讯作者:
    J. Wagner;Zoltán Járai;S. Batkai;George Kunos
The rat alpha 1B adrenergic receptor gene middle promoter contains multiple binding sites for sequence-specific proteins including a novel ubiquitous transcription factor.
大鼠 α1B 肾上腺素能受体基因中间启动子含有多个序列特异性蛋白质的结合位点,包括一种新型普遍存在的转录因子。
alpha-2-Adrenergic activation of proopiomelanocortin-containing neurons in the arcuate nucleus causes opioid-mediated hypotension and bradycardia.
弓状核中含有原阿黑皮质素的神经元的 α2-肾上腺素能激活会导致阿片类药物介导的低血压和心动过缓。
  • DOI:
    10.1159/000126966
  • 发表时间:
    1996
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Li,SJ;Scanlon,MN;Járai,Z;Varga,K;Gantenberg,NS;Lazar-Wesley,E;Kunos,G
  • 通讯作者:
    Kunos,G
Alpha-adrenergic inhibition of proliferation in HepG2 cells stably transfected with the alpha1B-adrenergic receptor through a p42MAPkinase/p21Cip1/WAF1-dependent pathway.
通过 p42MAPkinase/p21Cip1/WAF1 依赖性途径稳定转染 α1B 肾上腺素受体的 HepG2 细胞中,α 肾上腺素能抑制增殖。
  • DOI:
    10.1016/s0014-5793(98)01074-6
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Auer,KL;Spector,MS;Tombes,RM;Seth,P;Fisher,PB;Gao,B;Dent,P;Kunos,G
  • 通讯作者:
    Kunos,G
Cardiovascular effects of endocannabinoids--the plot thickens.
内源性大麻素对心血管的影响——情节变得更加复杂。
  • DOI:
    10.1016/s0090-6980(00)00056-3
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Kunos,G;Járai,Z;Varga,K;Liu,J;Wang,L;Wagner,JA
  • 通讯作者:
    Wagner,JA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE KUNOS其他文献

GEORGE KUNOS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE KUNOS', 18)}}的其他基金

NOVEL ENDOGENOUS CARDIOVASCULAR REGULATORS
新型内源性心血管调节剂
  • 批准号:
    2702586
  • 财政年份:
    1998
  • 资助金额:
    $ 19.73万
  • 项目类别:
NOVEL ENDOGENOUS CARDIOVASCULAR REGULATORS
新型内源性心血管调节剂
  • 批准号:
    6044008
  • 财政年份:
    1998
  • 资助金额:
    $ 19.73万
  • 项目类别:
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF ETHANOL
乙醇的中枢介导的心血管作用
  • 批准号:
    2000312
  • 财政年份:
    1995
  • 资助金额:
    $ 19.73万
  • 项目类别:
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF ETHANOL
乙醇的中枢介导的心血管作用
  • 批准号:
    2045971
  • 财政年份:
    1995
  • 资助金额:
    $ 19.73万
  • 项目类别:
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF ETHANOL
乙醇的中枢介导的心血管作用
  • 批准号:
    2045970
  • 财政年份:
    1995
  • 资助金额:
    $ 19.73万
  • 项目类别:
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF ETHANOL
乙醇的中枢介导的心血管作用
  • 批准号:
    2045969
  • 财政年份:
    1995
  • 资助金额:
    $ 19.73万
  • 项目类别:
ENDORPHINERGIC NEURONS AND CARDIOVASCULAR REGULATION
内啡肽神经元和心血管调节
  • 批准号:
    2225994
  • 财政年份:
    1994
  • 资助金额:
    $ 19.73万
  • 项目类别:
ENDORPHINERGIC NEURONS AND CARDIOVASCULAR REGULATION
内啡肽神经元和心血管调节
  • 批准号:
    2225990
  • 财政年份:
    1994
  • 资助金额:
    $ 19.73万
  • 项目类别:
ENDORPHINERGIC NEURONS AND CARDIOVASCULAR REGULATION
内啡肽神经元和心血管调节
  • 批准号:
    837217
  • 财政年份:
    1994
  • 资助金额:
    $ 19.73万
  • 项目类别:
ENDORPHINERGIC NEURONS AND CARDIOVASCULAR REGULATION
内啡肽神经元和心血管调节
  • 批准号:
    2225992
  • 财政年份:
    1994
  • 资助金额:
    $ 19.73万
  • 项目类别:

相似海外基金

The role of antihypertensive agents in renal and vascular complications in a model of hypertension and diabetes
抗高血压药物在高血压和糖尿病模型中肾脏和血管并发症中的作用
  • 批准号:
    nhmrc : 145854
  • 财政年份:
    2001
  • 资助金额:
    $ 19.73万
  • 项目类别:
    NHMRC Postgraduate Scholarships
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    6125791
  • 财政年份:
    1997
  • 资助金额:
    $ 19.73万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    2487342
  • 财政年份:
    1997
  • 资助金额:
    $ 19.73万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    2839029
  • 财政年份:
    1997
  • 资助金额:
    $ 19.73万
  • 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
  • 批准号:
    6330091
  • 财政年份:
    1997
  • 资助金额:
    $ 19.73万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    2217036
  • 财政年份:
    1993
  • 资助金额:
    $ 19.73万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    3343932
  • 财政年份:
    1993
  • 资助金额:
    $ 19.73万
  • 项目类别:
ANTIHYPERTENSIVE AGENTS FROM RANUNCULACEAE
毛茛科抗高血压药
  • 批准号:
    2217037
  • 财政年份:
    1993
  • 资助金额:
    $ 19.73万
  • 项目类别:
CANNABINOIDS AS ANTIHYPERTENSIVE AGENTS
大麻素作为抗高血压药
  • 批准号:
    3500707
  • 财政年份:
    1985
  • 资助金额:
    $ 19.73万
  • 项目类别:
Antihypertensive Agents of Kudzu: Possible Chemical Utilization of a Southeastern Pest Vine
葛根的抗高血压剂:东南部害虫藤蔓的可能化学利用
  • 批准号:
    7905238
  • 财政年份:
    1979
  • 资助金额:
    $ 19.73万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了